Ubs Group Ag Nls Pharmaceutics Ltd. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Nls Pharmaceutics Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 235,723 shares of NLSP stock, worth $33,001. This represents 0.0% of its overall portfolio holdings.

Number of Shares

235,723

Holding current value

$33,001

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.11 - $0.27 $25,929 - $63,645	235,723 New	235,723 $51,000
Q2 2023 Aug 11, 2023	BUY	$0.92 - $1.56 $3,133 - $5,313	3,406 New	3,406 $3,000
Q4 2022 Feb 08, 2023	BUY	$0.48 - $1.29 $4,723 - $12,693	9,840 New	9,840 $12,000
Q2 2022 Aug 10, 2022	BUY	$0.53 - $1.36 $2,475 - $6,351	4,670 Added 44.13%	15,252 $9,000
Q1 2022 May 16, 2022	SELL	$0.82 - $1.76 $1,795 - $3,854	-2,190 Reduced 17.15%	10,582 $15,000
Q4 2021 Feb 14, 2022	SELL	$1.11 - $2.56 $55,168 - $127,234	-49,701 Reduced 79.56%	12,772 $14,000
Q3 2021 Nov 15, 2021	BUY	$2.29 - $3.14 $138,654 - $190,120	60,548 Added 3145.35%	62,473 $156,000
Q2 2021 Aug 13, 2021	BUY	$2.91 - $4.12 $5,601 - $7,931	1,925 New	1,925 $6,000

Others Institutions Holding NLSP

# of Institutions

Shares Held

8.53M

Call Options Held

Put Options Held

Bvf Inc San Francisco, CA

5.75M
Shares

$804,597
0.04% of portfolio
Armistice Capital, LLC New York, NY

2.31M
Shares

$323,540
0.01% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

136K
Shares

$19,077
0.0% of portfolio
Jane Street Group, LLC New York, NY

43.7K
Shares

$6,114
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

21.8K
Shares

$3,048
0.0% of portfolio

View Full List

About NLS Pharmaceutics Ltd.

Ticker NLSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,349,900
Market Cap $4.11M
Description
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, suc...

More about NLSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account